ArticleCureus2025
Diagnostic Value of Inflammatory Markers in Inflammatory Bowel Disease: Clinical and Endoscopic Correlations.
Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- Habitual Ultra-processed Food Intake Is Associated with Gut Dysbiosis and Pro-inflammatory Metabolite Profiles in Korean Patients with IBD.Digestive diseases and sciences · 2026Article
- Tissue Eosinophilia of the Colonic Mucosa as a Potential Early Predictor of Failure to Achieve Clinical Remission in Ulcerative Colitis.Medicina (Kaunas, Lithuania) · 2026Article
- Alleviating Effects ofInternational journal of molecular sciences · 2026Article
- Lipoprotein (a) and inflammatory bowel disease: a systematic review and meta-analysis.Annals of gastroenterology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background The incidence of inflammatory bowel diseases (IBD) has increased over the last century. Despite the unclear etiology of IBD, significant advancements have been made in recent years to understand the development of this disease. Objectives The aim of this study was to examine the diagnostic significance of several inflammatory biomarkers and their associations with clinical and endoscopic disease activity in patients with IBD. Methods This case-control study involved 68 patients, 34 with Crohn's disease (CD) and 34 with ulcerative colitis (UC), with IBD confirmed by endoscopy and histopathology, and 52 healthy subjects as a control group. A pre-designed questionnaire was completed for each subject. Stool samples were taken for fecal calprotectin (FC) measurement by enzyme-linked immunosorbent assay (ELISA), and a blood sample was obtained for complete blood and differential counts using a hematology autoanalyzer, erythrocyte sedimentation rate (ESR), serum C-reactive protein (CRP) by Cobas (Roche Diagnostics, Basel, Switzerland), and measurements of interleukins (IL-6, IL-17A, IL-8, and IL-1β) by ELISA. Comparisons of parameters were considered statistically significant at the P < 0.05 interval. Results The mean levels of ESR, CRP, FC, all measured ILs, neutrophil number and percentage (%), neutrophil-lymphocyte ratio (NLR), and platelet number were statistically significantly higher in patients with IBD compared to the control group. However, lymphocyte%, lymphocyte-mid-size leukocytes ratio (LMR), hemoglobin, mean corpuscular hemoglobin (MCH), hematocrit, and red cell distribution width (RDW) were significantly lower in patients with IBD compared to controls. Receiver operating characteristic (ROC) curve analyses showed that FC, IL-8, and ESR, respectively, have the highest area under the curve (AUC) and were of the highest validity to differentiate between patients with IBD and healthy subjects, followed by CRP and IL-1β. Conclusion All the studied ILs were increased in patients with IBD; their increases were not different between UC and CD patients. FC, IL-8, and ESR were of the highest validity for the diagnosis of IBD. Findings collectively highlight the validity of the measured parameters as potential biomarkers in IBD.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.